贫白细胞富血小板血浆作为关节镜下肩袖修复辅助治疗降低再撕裂率但不改善功能结局:一项双盲随机对照试验
该双盲随机对照试验在单中心连续纳入96例肩袖撕裂<3 cm患者,随机分为对照组(单纯双排缝线桥关节镜下肩袖修复,n=48)和PRP组(双排缝线桥修复后术中注射1次贫白细胞富血小板血浆(LP-PRP),n=48)。PRP组再撕裂率为15.2%(7/46),低于对照组的34.1%(15/44),差异有统计学意义(P=0.037);但两组功能评分无显著差异。
要点
- PRP组再撕裂率15.2%(7/46)低于对照组34.1%(15/44),P=0.037。
- LP-PRP组撕裂风险比为0.44(95%CI 0.2-0.9;P=0.037)。
- 两组ASES、VAS、SANE、PSQI评分无显著差异,功能结局未获益。
核心结论
- 对于肩袖撕裂<3 cm行双排缝线桥修复的患者,术中于腱-骨界面注射5 mL剂量LP-PRP显著降低再撕裂率。
- LP-PRP在术后疼痛和患者报告结局方面未能显示出有临床意义的效应。
研究设计与样本
- 双盲随机对照试验,证据等级1级,单中心进行。
- 连续纳入96例肩袖撕裂<3 cm患者,随机分为对照组(单纯双排缝线桥关节镜下肩袖修复,n=48)和PRP组(双排缝线桥修复后术中注射1次LP-PRP,n=48)。
- 患者和评估者均对术中接受的干预设盲。
主要发现
- 患者平均年龄56.1±2.98岁;96例中90例在术后6个月完成MRI(放射学随访率94%)。
- PRP组再撕裂率为15.2%(7/46 [95%CI 6%-28%]),低于对照组的34.1%(15/44 [95%CI 20%-49%])(P=0.037)。
- 暴露于LP-PRP的患者撕裂风险比为0.44(95%CI 0.2-0.9;P=0.037)。
- 总体上,ASES、VAS、SANE和PSQI评分在术后显示统计学改善(P<0.001)。
- 两组间功能评分无显著差异;大多数患者超过ASES、SANE和VAS的最小临床重要差异,组间无显著差异。
关键数值与推荐
- PRP组再撕裂率15.2%(7/46 [95%CI 6%-28%])vs 对照组34.1%(15/44 [95%CI 20%-49%])(P=0.037)。
- LP-PRP组撕裂风险比0.44(95%CI 0.2-0.9;P=0.037)。
- ASES、VAS、SANE、PSQI评分术后均 statistical improvement(P<0.001),组间功能评分无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether the use of PRP as an adjuvant of rotator cuff repairs leads to improved tendon healing and better functional outcomes remains unclear in clinical evidence. PURPOSE: The main purpose of this study was to assess whether the use of leukocyte-poor platelet-rich plasma (LP-PRP) as an adjuvant to arthroscopic rotator cuff repair (ARCR) decreases the rate of retears compared with a control group. The secondary objective was to analyze whether LP-PRP improves patient-reported outcomes. STUDY DESIGN: Randomized controlled trial; Level of evidence, 1. METHODS: This was a double-blind randomized controlled trial at a single center. A consecutive series of 96 patients with rotator cuff tears <3 cm were enrolled and randomly allocated to the control group (double-row suture-bridge ARCR alone [n = 48]) and the PRP group (double-row suture-bridge repair, followed by 1 LP-PRP injection during surgery [n = 48]). The visual analog scale (VAS) for pain, the American Shoulder and Elbow Surgeons (ASES) score, the Single Assessment Numeric Evaluation (SANE), and the Pittsburgh Sleep Quality Index (PSQI) were administered preoperatively and at 6- and 12-month follow-up. Magnetic resonance imaging (MRI) was performed to evaluate tendon integrity at 6-month follow-up. Both patients and assessors were blinded to the intervention received during surgery. RESULTS: The mean patient age was 56.1 ± 2.98 years. Of the 96 patients, 90 had MRI performed at 6 months after surgery (94% radiological follow-up). The retear rate in the PRP group was 15.2% (7/46 [95% CI, 6%-28%]), which was lower than that in the control group of 34.1% (15/44 [95% CI, 20%-49%]) (P = .037). Therefore, the risk ratio of ruptures in patients exposed to LP-PRP was 0.44 (95% CI, 0.2-0.9; P = .037). Overall, the ASES, VAS, SANE, and PSQI scores showed a statistical improvement after surgery (P < .001). There were no significant differences in functional scores between the groups. Most of the patients exceeded the minimal clinically important difference for the ASES, SANE, and VAS without significant differences between the groups. CONCLUSION: In patients with rotator cuff tears <3 cm undergoing double-row suture-bridge repair, a 5-mL dose of LP-PRP injected at the tendon-bone interface significantly reduced the retear rate. However, the use of LP-PRP in terms of postoperative pain and patient-reported outcomes failed to show clinically meaningful effects. REGISTRATION: NCT04703998 (ClinicalTrials.gov identifier).
引用
- Rossi LA, Gorodischer TD, Camino P, et al. Leukocyte-Poor Platelet-Rich Plasma as an Adjuvant to Arthroscopic Rotator Cuff Repair Reduces the Retear Rate But Does Not Improve Functional Outcomes: A Double-Blind Randomized Controlled Trial. Am J Sports Med. 2024. PMID: 38587033. doi:10.1177/03635465241239062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。